<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">33314436</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>A novel temporal-predominant&#xa0;neuro-astroglial tauopathy&#xa0;associated with TMEM106B gene polymorphism in FTLD/ALS-TDP.</ArticleTitle><Pagination><StartPage>267</StartPage><EndPage>282</EndPage><MedlinePgn>267-282</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.12924</ELocationID><Abstract><AbstractText>Polymorphisms in TMEM106B, a gene on chromosome 7p21.3 involved in lysosomal trafficking, correlates to worse neuropathological, and clinical outcomes in frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) with TDP-43 inclusions. In a small cohort of C9orf72 expansion carriers, we previously found an atypical, neuroglial tauopathy in cases harboring a TMEM106B rs1990622 A/A genotype. To test whether TMEM106B genotype affects the risk of developing atypical tauopathy under a recessive genotype model (presence versus absence of two major alleles: A/A vs. A/G and G/G). We characterized the atypical tauopathy neuropathologically and determined its frequency by TMEM106B rs1990622 genotypes in 90 postmortem cases with a primary diagnosis of FTLD/ALS-TDP [mean age at death 65.5&#xa0;years (&#xb1;8.1), 40% female]. We investigated the effect of this new atypical tauopathy on demographics and clinical and neuropsychological metrics. We also genotyped TMEM106B in an independent series with phenotypically similar cases. Sixteen cases (16/90, 17.7 %) showed the temporal-predominant&#xa0;neuro-astroglial tauopathy, and 93.7% of them carried an A/A genotype (vs. ~35% in a population cohort). The odds ratio of FTLD/ALS-TDP individuals with the A/A genotype showing neuro-astroglial tauopathy was 13.9. Individuals with this tauopathy were older at onset (p&#xa0;=&#xa0;0.01). The validation cohort had a similarly high proportion of rs1990622 A/A genotype. TDP-43 and tau changes co-occur in a subset of neurons. Our data add to the growing body of evidence that TMEM106B polymorphisms may modulate neurodegeneration. A distinctive medial temporal predominant, 4-repeat, neuro-astroglial tauopathy strongly correlates to TMEM106B A/A genotype in FTLD/ALS-TDP cases.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Llibre-Guerra</LastName><ForeName>Jorge J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Neurology and Neurosurgery, La Habana, Cuba.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Suzee E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suemoto</LastName><ForeName>Claudia K</ForeName><Initials>CK</Initials><Identifier Source="ORCID">0000-0002-5942-4778</Identifier><AffiliationInfo><Affiliation>Biobank for Aging Studies, LIM-22, Department of Pathology, University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Geriatrics, Department of Clinical Medicine, University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ehrenberg</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Integrative Biology, University of California, Berkeley, Berkeley, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kovacs</LastName><ForeName>Gabor G</ForeName><Initials>GG</Initials><Identifier Source="ORCID">0000-0003-3841-5511</Identifier><AffiliationInfo><Affiliation>Institute of Neurology, Medical University Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory Medicine Program &amp; Krembil Brain Institute, University Health Network, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karydas</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staffaroni</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franca Resende</LastName><ForeName>Elisa De Paula</ForeName><Initials>EP</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Grupo de Pesquisa em Neurologia Cognitiva e do Comportamento, Departamento de Cl&#xed;nica M&#xe9;dica, Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Eun-Joo</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Medical Research Institute, Busan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Ji-Hye</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Eliana Marisa</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wojta</LastName><ForeName>Kevin J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasquini</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Shirley Yin-Yu</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Division of Neurology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spina</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Isabel E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology &amp; Biostatistics, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Bruce L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seeley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grinberg</LastName><ForeName>Lea T</ForeName><Initials>LT</Initials><Identifier Source="ORCID">0000-0002-6809-0618</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Brain Health Institute, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biobank for Aging Studies, LIM-22, Department of Pathology, University of Sao Paulo Medical School, Sao Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology and Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AG058233</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS100717</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG053435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG057528</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 AG062422</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG070826</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 AG061253</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K99 AG065457</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2018-A-025</GrantID><Agency>Larry L. Hillblom Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C556915">TMEM106B protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">
TMEM106B
</Keyword><Keyword MajorTopicYN="N">Rs1990622</Keyword><Keyword MajorTopicYN="N">TDP-43 proteinopathy</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">genetic association</Keyword><Keyword MajorTopicYN="N">neuropathologic diagnosis</Keyword><Keyword MajorTopicYN="N">polymorphism</Keyword><Keyword MajorTopicYN="N">risk factor</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList><CoiStatement>Jorge J. Llibre&#x2010;Guerra, Suzee E. Lee, Claudia K Suemoto, Gabor G. Kovacs, Anna Karydas, Adam Staffaroni, Elisa De Paula Franca Resende, Eun&#x2010;Joo Kim, Eliana Marisa Ramos, Kevin J. Wojta, Shirley Pang, Lorenzo Pasquini, Salvatore Spina, Joel Kramer, Ji&#x2010;Hye Hwang, Isabel E. Allen, William W. Seeley, Bruce L. Miller, and Lea T. Grinberg: reports no conflict of interest related to this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>14</Day><Hour>11</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33314436</ArticleId><ArticleId IdType="mid">NIHMS1665757</ArticleId><ArticleId IdType="pmc">PMC7946775</ArticleId><ArticleId IdType="doi">10.1111/bpa.12924</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ferrari R, Hernandez DG, Nalls MA, Rohrer JD, Ramasamy A, Kwok JB, et al. Frontotemporal dementia and its subtypes: a genome&#x2010;wide association study. Lancet Neurol. 2014;13(7):686&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4112126</ArticleId><ArticleId IdType="pubmed">24943344</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinagawa S, Naasan G, Karydas AM, Coppola G, Pribadi M, Seeley WW, et al. Clinicopathological study of patients with C9ORF72&#x2010;associated frontotemporal dementia presenting with delusions. J Geriatr Psychiatry Neurol. 2015;28(2):99&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4408221</ArticleId><ArticleId IdType="pubmed">25342578</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N, et al. Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch Neurol. 2011;68(5):581&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3090529</ArticleId><ArticleId IdType="pubmed">21220649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, et al. TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 2014;127(3):407&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4003885</ArticleId><ArticleId IdType="pubmed">24442578</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Ravenscroft TA, Sanchez&#x2010;Contreras M, Rademakers R. Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem. 2016;138(Suppl 1):32&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27009575</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez&#x2010;Lage M, Chen&#x2010;Plotkin A, Wang LS, Graff&#x2010;Radford NR, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP&#x2010;43 inclusions. Nat Genet. 2010;42(3):234&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Broeckhoven C. TMEM106B a novel risk factor for frontotemporal lobar degeneration. J Mol Neurosci. 2011;45(3):516&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207134</ArticleId><ArticleId IdType="pubmed">21614538</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S, Vandenberghe R, et al. TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain. 2011;134(Pt 3):808&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3044834</ArticleId><ArticleId IdType="pubmed">21354975</ArticleId></ArticleIdList></Reference><Reference><Citation>Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus&#x2010;Hernandez M, et al. TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology. 2011;76(5):467&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3034409</ArticleId><ArticleId IdType="pubmed">21178100</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez I, Rosende&#x2010;Roca M, Alegret M, Mauleon A, Espinosa A, Vargas L, et al. Association of TMEM106B rs1990622 marker and frontotemporal dementia: evidence for a recessive effect and meta&#x2010;analysis. J Alzheimers Dis. 2015;43(1):325&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">25096617</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, Schneider JA. The TMEM106B locus and TDP&#x2010;43 pathology in older persons without FTLD. Neurology. 2015;84(9):927&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351662</ArticleId><ArticleId IdType="pubmed">25653292</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Smith CD, Abner EL, Wilfred BJ, Wang WX, Neltner JH, et al. Hippocampal sclerosis of aging, a prevalent and high&#x2010;morbidity brain disease. Acta Neuropathol. 2013;126(2):161&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3889169</ArticleId><ArticleId IdType="pubmed">23864344</ArticleId></ArticleIdList></Reference><Reference><Citation>Nho K, Saykin AJ, Alzheimer's Disease Neuroimaging I, Nelson PT. Hippocampal sclerosis of aging, a common Alzheimer's disease &#x2018;Mimic&#x2019;: risk genotypes are associated with brain atrophy outside the temporal lobe. J Alzheimers Dis. 2016;52(1):373&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4978172</ArticleId><ArticleId IdType="pubmed">27003218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun MH, Han JH, Lee YK, Jang DJ, Kaang BK, Lee JA. TMEM106B, a frontotemporal lobar dementia (FTLD) modifier, associates with FTD&#x2010;3&#x2010;linked CHMP2B, a complex of ESCRT&#x2010;III. Mol Brain. 2015;8:85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676093</ArticleId><ArticleId IdType="pubmed">26651479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB 3rd, Castanedes&#x2010;Casey M, et al. TMEM106B p. T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J Neurochem. 2013;126(6):781&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766501</ArticleId><ArticleId IdType="pubmed">23742080</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, et al. Loss of TMEM106B ameliorates lysosomal and frontotemporal dementia&#x2010;related phenotypes in progranulin&#x2010;deficient mice. Neuron. 2017;95(2):281&#x2013;96.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5558861</ArticleId><ArticleId IdType="pubmed">28728022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kao AW, McKay A, Singh PP, Brunet A, Huang EJ. Progranulin, lysosomal regulation and neurodegenerative disease. Nat Rev Neurosci. 2017;18(6):325&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6040832</ArticleId><ArticleId IdType="pubmed">28435163</ArticleId></ArticleIdList></Reference><Reference><Citation>Paushter DH, Du H, Feng T, Hu F. The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathol. 2018;136(1):1&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6117207</ArticleId><ArticleId IdType="pubmed">29744576</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez RD, Suemoto CK, Molina M, Nascimento CF, Leite RE, de Lucena Ferretti&#x2010;Rebustini RE, et al. Argyrophilic grain disease: demographics, clinical, and neuropathological features from a large autopsy study. J Neuropathol Exp Neurol. 2016;75(7):628&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4913431</ArticleId><ArticleId IdType="pubmed">27283329</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Ferrer I, Grinberg LT, Alafuzoff I, Attems J, Budka H, et al. Aging&#x2010;related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 2016;131(1):87&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4879001</ArticleId><ArticleId IdType="pubmed">26659578</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Molnar K, Laszlo L, Strobel T, Botond G, Honigschnabl S, et al. A peculiar constellation of tau pathology defines a subset of dementia in the elderly. Acta Neuropathol. 2011;122(2):205&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">21437732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer JH, Jurik J, Sha SJ, Rankin KP, Rosen HJ, Johnson JK, et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol. 2003;16(4):211&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14665820</ArticleId></ArticleIdList></Reference><Reference><Citation>Perry DC, Brown JA, Possin KL, Datta S, Trujillo A, Radke A, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2017;140(12):3329&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841140</ArticleId><ArticleId IdType="pubmed">29053860</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranasinghe KG, Rankin KP, Pressman PS, Perry DC, Lobach IV, Seeley WW, et al. Distinct subtypes of behavioral variant frontotemporal dementia based on patterns of network degeneration. JAMA Neurol. 2016;73(9):1078&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5024785</ArticleId><ArticleId IdType="pubmed">27429218</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos EM, Dokuru DR, Van Berlo V, Wojta K, Wang Q, Huang AY, et al. Genetic screen in a large series of patients with primary progressive aphasia. Alzheimers Dement. 2019;15(4):553&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6480353</ArticleId><ArticleId IdType="pubmed">30599136</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22002422</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Bigio EH, Mackenzie IRA, Neumann M, Lee VMY, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007;114(1):5&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827877</ArticleId><ArticleId IdType="pubmed">17579875</ArticleId></ArticleIdList></Reference><Reference><Citation>Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging&#x2010;Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3268003</ArticleId><ArticleId IdType="pubmed">22101365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD&#x2010;TDP pathology. Acta Neuropathol. 2011;122(1):111&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Bigio EH, Cairns NJ, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2799633</ArticleId><ArticleId IdType="pubmed">19924424</ArticleId></ArticleIdList></Reference><Reference><Citation>McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies &#x2010; Third report of the DLB consortium. Neurology. 2005;65(12):1863&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">16237129</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Cairns NJ, Dickson DW, Folkerth RD, Keene CD, Litvan I, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016;131(1):75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4698281</ArticleId><ArticleId IdType="pubmed">26667418</ArticleId></ArticleIdList></Reference><Reference><Citation>Grinberg LT, Wang X, Wang C, Sohn PD, Theofilas P, Sidhu M, et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 2013;125(4):581&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692283</ArticleId><ArticleId IdType="pubmed">23371364</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding SR, Bocchetta M, Gordon E, Cash DM, Cardoso MJ, Druyeh R, et al. The TMEM106B risk allele is associated with lower cortical volumes in a clinically diagnosed frontotemporal dementia cohort. J Neurol Neurosurg Psychiatry. 2017;88(11):997&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5740537</ArticleId><ArticleId IdType="pubmed">28446602</ArticleId></ArticleIdList></Reference><Reference><Citation>Delis DC, Kaplan E, Kramer JH. Delis&#x2010;Kaplan Executive Function System (D&#x2010;KEFS): examiner's manual. San Antonio, TX: The Psychological Corporation; 2001.</Citation></Reference><Reference><Citation>Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology. 1935;18:643&#x2013;62.</Citation></Reference><Reference><Citation>Dunn L, Dunn D. Peabody picture vocabulary test. 4th ed. Minneapolis, MN: Pearson Assessments; 2007.</Citation></Reference><Reference><Citation>Staffaroni AM, Brown JA, Casaletto KB, Elahi FM, Deng J, Neuhaus J, et al. The longitudinal trajectory of default mode network connectivity in healthy older adults varies as a function of age and is associated with changes in episodic memory and processing speed. J Neurosci. 2018;38(11):2809&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5852659</ArticleId><ArticleId IdType="pubmed">29440553</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Knopman DS, Hu WT, Stroh DA, Baker M, et al. Abnormal TDP&#x2010;43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology. 2008;70(19 Pt 2):1850&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2779031</ArticleId><ArticleId IdType="pubmed">18401022</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno F, Rabinovici GD, Karydas A, Miller Z, Hsu SC, Legati A, et al. A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques. Acta Neuropathol Commun. 2015;3:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382926</ArticleId><ArticleId IdType="pubmed">25853458</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, Zheng Y, Murphy K, Huang M, Hu F. The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum Mol Genet. 2013;22(4):685&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554197</ArticleId><ArticleId IdType="pubmed">23136129</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch JI, Unger TL, Jain N, Tyler Skrinak R, Charan RA, Chen&#x2010;Plotkin AS. Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72&#x2010;dependent alterations in lysosomes. Hum Mol Genet. 2016;25(13):2681&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5181637</ArticleId><ArticleId IdType="pubmed">27126638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhinn H, Abeliovich A. Differential aging analysis in human cerebral cortex identifies variants in TMEM106B and GRN that regulate aging phenotypes. Cell Syst. 2017;4(4):404&#x2013;15.e5.</Citation><ArticleIdList><ArticleId IdType="pubmed">28330615</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu RC, Wang H, Tan MS, Yu JT, Tan L. TMEM106B and APOE polymorphisms interact to confer risk for late&#x2010;onset Alzheimer's disease in Han Chinese. J Neural Transm (Vienna). 2014;121(3):283&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166182</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Wang WX, Partch AB, Monsell SE, Valladares O, Ellingson SR, et al. Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol. 2015;74(1):75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270894</ArticleId><ArticleId IdType="pubmed">25470345</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh J, Kino Y, Kawana N, Yamamoto Y, Ishida T, Saito Y, et al. TMEM106B expression is reduced in Alzheimer's disease brains. Alzheimers Res Ther. 2014;6(2):17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4055042</ArticleId><ArticleId IdType="pubmed">24684749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry JD, Mez J, Crary JF, Tripodis Y, Alvarez VE, Mahar I, et al. Variation in TMEM106B in chronic traumatic encephalopathy. Acta Neuropathol Commun. 2018;6(1):115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215686</ArticleId><ArticleId IdType="pubmed">30390709</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129(4):469&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369168</ArticleId><ArticleId IdType="pubmed">25549971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Kwong LK, Grossman M, Irwin DJ, Lee EB, Robinson JL, et al. Tauopathy with hippocampal 4&#x2010;repeat tau immunoreactive spherical inclusions: a report of three cases. Brain Pathol. 2018;28(2):274&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5484758</ArticleId><ArticleId IdType="pubmed">28019685</ArticleId></ArticleIdList></Reference><Reference><Citation>Debaisieux S, Schiavo G. TiME for TMEM106B. EMBO J. 2014;33(5):405&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989622</ArticleId><ArticleId IdType="pubmed">24497553</ArticleId></ArticleIdList></Reference><Reference><Citation>Vass R, Ashbridge E, Geser F, Hu WT, Grossman M, Clay&#x2010;Falcone D, et al. Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathol. 2011;121(3):373&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3095217</ArticleId><ArticleId IdType="pubmed">21104415</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y, Hartley T, Baird S, Venkateswaran S, Simons C, Wolf NI, et al. Lysosomal dysfunction in TMEM106B hypomyelinating leukodystrophy. Neurol Genet. 2018;4(6):e288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6317987</ArticleId><ArticleId IdType="pubmed">30643851</ArticleId></ArticleIdList></Reference><Reference><Citation>Luningschror P, Werner G, Stroobants S, Kakuta S, Dombert B, Sinske D, et al. The FTLD risk factor TMEM106B regulates the transport of lysosomes at the axon initial segment of motoneurons. Cell Rep. 2020;30(10):3506&#x2013;19.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32160553</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Farias FHG, Dube U, Del&#x2010;Aguila JL, Mihindukulasuriya KA, Fernandez MV, et al. The TMEM106B FTLD&#x2010;protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathol. 2020;139(1):45&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6942643</ArticleId><ArticleId IdType="pubmed">31456032</ArticleId></ArticleIdList></Reference><Reference><Citation>Bieniek KF, Murray ME, Rutherford NJ, Castanedes&#x2010;Casey M, DeJesus&#x2010;Hernandez M, Liesinger AM, et al. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol. 2013;125(2):289&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551994</ArticleId><ArticleId IdType="pubmed">23053135</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolan A, Resende EDPF, Petersen C, Neylan K, Spina S, Huang E, et al. Astrocytic tau deposition is frequent in typical and atypical alzheimer disease presentations. J Neuropathol Exp Neurol. 2019;78(12):1112&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967845</ArticleId><ArticleId IdType="pubmed">31626288</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, et al. Corticobasal degeneration with TDP&#x2010;43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathol. 2018;136: 389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309287</ArticleId><ArticleId IdType="pubmed">29926172</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>